辉瑞曾开发另一种口服GLP-1药物lotiglipron，但在临床试验中发现其可能具有肝毒性，公司最终在2023年6月终止开发该药物。 封面图片来源：视觉中国 ...

2月4日，辉瑞公布了2024年业绩，第四季度营收177.63亿美元，同比增长21%，全年实现营收636.27亿美元，同比增长7%，若排除新冠 ...

Good day, everyone, and welcome to Pfizer's Fourth Quarter 2024 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino ...

(Reuters) -Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as it aims to show investors steadier execution and growth after ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.” In an investor presentation (PDF) Tuesday ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. The Big Pharma disclosed the blow alongside a $200 million charge linked ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance (5) provided on December 17, 2024. The ...

Pfizer (NYSE:PFE) just dropped some big news, and it's a game-changer for cancer treatment. The company announced top-tier results from its Phase 3 BREAKWATER trial of BRAFTOVI (encorafenib) in ...

Merck is battling selling pressure, but strong analyst targets suggest upside potential. Pfizer faces a bearish trend with minimal upside, though analysts expect a moderate gain. Get two weeks of ...

Ahead of next Tuesday's earnings release, Pfizer seems undervalued based on current price of $26.55 & valuation of $150bn. But is it madness to expect upside? Quite possibly it is. My DCF analysis ...

Activist Starboard Value has decided not to pursue a proxy battle with Pfizer. Starboard built a $1 billion stake in Pfizer in October and reportedly planned to push for changes. Get two weeks of ...

Recently, Pfizer found itself in the agency's crosshairs thanks to one of its M&A plays. Now, Pfizer—which purchased neuroscience specialist Biohaven for $11.6 billion in 2022—is committing ...